Survival Outcomes of Treatment Modalities in Patients with Variant Histopathology of Bladder Cancer in First Transurethral Resection of the Bladder

Basit Öğe Kaydı
dc.authoridCelik, Serdar/0000-0003-0939-9989
dc.authoridBaltaci, Sumer/0000-0002-7604-841X
dc.authoridIzol, Volkan/0000-0001-5007-6781
dc.authoridAKGUL, MURAT/0000-0001-6187-1940
dc.contributor.authorIzol, Volkan
dc.contributor.authorDeger, Mutlu
dc.contributor.authorAkdogan, Buelent
dc.contributor.authorAkguel, Murat
dc.contributor.authorAslan, Gueven
dc.contributor.authorCelik, Serdar
dc.contributor.authorArgun, Burak
dc.date.accessioned2024-10-29T17:59:40Z
dc.date.available2024-10-29T17:59:40Z
dc.date.issued2024
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractObjective: Diagnoses of variant histopathology (VH) in bladder cancer (BC) are increasing, and although there is a standard treatment algorithm for BC, the guidelines lack a standardized approach for treating VH in BC. We aimed to compare the survival results of the treatment algorithm applied to patients with BC with Materials and Methods: We retrospectively assessed data on patients with VH of BC in the first TUR-B between January 2000 and January 2021. After the first TUR-B, we determined TUR-B+/- BCG, radical cystectomy (RC), and trimodal therapy (TMT) as the three potential treatments for patients according to the initial Results: A total of 289 patients with VH of BC in the first TUR-B were included in the study. Their mean age was 66.7 +/- 10.1 years, and most (246, 85.1%) were male. We found that TMT was associated with lower survival, and BCG administration offered no advantage in terms of overall survival (OS) or cancer specific survival (CSS) among patients with non-muscle-invasive bladder cancer (NMIBC). In patients with MIBC, immediate RC provided a significant advantage over other Conclusions: There is still no standard treatment for patients with VH of BC. Patients are less likely to survive TMT than other treatment modalities.
dc.identifier.doi10.4274/uob.galenos.2023.2023.8.1
dc.identifier.endpage28
dc.identifier.issn2147-2270
dc.identifier.issue1en_US
dc.identifier.startpage22
dc.identifier.trdizinid#BAŞV!
dc.identifier.urihttps://doi.org/10.4274/uob.galenos.2023.2023.8.1
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1240868
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14804
dc.identifier.volume23
dc.identifier.wosWOS:001198126600007
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherGalenos Publ House
dc.relation.ispartofUroonkoloji Bulteni-Bulletin of Urooncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBladder cancer
dc.subjectvariant histopathology
dc.subjecttransurethral resection of bladder
dc.subjectradical cystectomy
dc.subjecttrimodal therapy
dc.titleSurvival Outcomes of Treatment Modalities in Patients with Variant Histopathology of Bladder Cancer in First Transurethral Resection of the Bladder
dc.title.alternativeSurvival Outcomes of Treatment Modalities in Patients with Variant Histopathology of Bladder Cancer in First Transurethral Resection of the Bladder
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu